SCHEMBL6824873

SCHEMBL6824873

Clc1ccc2[nH]c(Cc3ccccc3)cc2c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.60
F2 P00734 2/20 0.58
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
ALDH1A1 P00352 2/20 0.54
MAPT P10636 2/20 0.54
KDM4E B2RXH2 1/20 0.54
LMNA P02545 1/20 0.54
CYP19A1 P11511 1/20 0.54
SIRT1 Q96EB6 1/20 0.53
PCSK9 Q8NBP7 1/20 0.52
EGFR P00533 3/20 0.50
PYGL P06737 5/20 0.49
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
DAO P14920 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6826452 0.90 LOXL2 (0.64) LOXL2F2MEN1KMT2ANPC1
SCHEMBL6824328 0.89 LOXL2 (0.58) LOXL2F2MEN1KMT2ANPC1
SCHEMBL866136 0.86 LOXL2 (0.72) LOXL2MEN1KMT2ANPC1RAB9A
SCHEMBL8802664 0.84 LOXL2 (0.57) LOXL2F2MEN1KMT2ANPC1
SCHEMBL6989299 0.84 LOXL2 (0.57) LOXL2F2MEN1KMT2ANPC1
SCHEMBL12096730 0.82 SIRT1 (0.56) LOXL2F2MEN1KMT2ANPC1
SCHEMBL6619148 0.81 PCSK9 (0.57) LOXL2F2MEN1KMT2ANPC1
SCHEMBL6990842 0.81 MAOB (0.57) LOXL2F2ALDH1A1KDM4E
SCHEMBL6826669 0.81 PCSK9 (0.57) LOXL2F2MEN1KMT2ANPC1
SCHEMBL3193871 0.80 LOXL2 (0.60) LOXL2F2PCSK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R LOXL2 4801/4885F2 4553/4885MEN1 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.